Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and oncological diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017, Singapore in 2020, and Thailand in 2021; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US and Taiwan; LT2003, tumor-targeting enzyme prodrug; and LT5001, a novel topical drug for uremic pruritus.
Location: Taiwan
Employees: 11-50
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | YFY Biotec... | tgbfund.co... |
Mentions in press and media 3
| Date | Title | Description |
| 24.11.2025 | GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL,... |
| 02.02.2024 | Lumosa Therapeutics and CHI Memorial announce new study for acute stroke | TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute s... |
| 03.08.2021 | Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke | LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS ≥6 treated with LT3001. These data suggest that LT3001 ha... |